Shandong Spring Pharmaceutical

Shandong Spring Pharmaceutical (also known as Shandong Quangang Pharmaceutical) is a Chinese biopharmaceutical company specializing in the development and commercialization of recombinant protein drugs and innovative peptide therapies. The company's commercial portfolio includes the recombinant human interleukin-2 product Quanqi and the granulocyte colony-stimulating factor product Quansheng, which are used in oncology and hematology. Its research and development efforts are focused on multi-target peptide agonists for metabolic diseases, with lead candidates QG-0301 (a GLP-1/GIP dual agonist) and QG-0701 (a GLP-1/GIP/GCG tri-agonist) currently in clinical development for obesity, type 2 diabetes, and NASH. Headquartered in Jinan, Shandong, the company operates as a private entity following the 2020 revocation of its U.S. parent company's SEC registration. The company is recognized as a National High-tech Enterprise and maintains a strong manufacturing presence in Sishui County.